MDM2 SNP309 Contributes to Non-Small Cell Lung Cancer Survival in Chinese

被引:20
作者
Dong, Jing [2 ]
Ren, Binhui [3 ]
Hu, Zhibin [2 ,4 ]
Chen, Jiaping [2 ]
Hu, Lingmin [2 ]
Dai, Juncheng [2 ]
Jin, Guangfu [2 ]
Xu, Lin [3 ]
Shen, Hongbing [1 ,2 ,4 ]
机构
[1] Nanjing Med Univ, Dept Epidemiol & Biostat, Ctr Canc, Sch Publ Hlth,Key Lab Modern Toxicol, Nanjing 210029, Peoples R China
[2] Nanjing Med Univ, Minist Educ, Key Lab Modern Toxicol, Sch Publ Hlth, Nanjing 210029, Peoples R China
[3] Jiangsu Canc Hosp, Dept Thorac Surg, Nanjing, Peoples R China
[4] Nanjing Med Univ, Dept Clin Epidemiol, Ctr Canc, Nanjing 210029, Peoples R China
基金
中国国家自然科学基金;
关键词
MDM2; polymorphisms; NSCLC; prognosis; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC POLYMORPHISMS; ONCOPROTEIN MDM2; P53; PATHWAY; RISK; ASSOCIATION; PROMOTER; PROTEIN; SUSCEPTIBILITY; EPIDEMIOLOGY;
D O I
10.1002/mc.20727
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Murine double minute 2 (MDM2) is a negative regulator of the tumor suppressor gene p53. Single nucleotide polymorphisms in MDM2 and p53 can affect patient's response to chemotherapy as well as overall survival of many cancers. This study aimed to assess the associations between polymorphisms in MDM2 and p53 and survival of non-small cell lung cancer (NSCLC) patients in Chinese. We selected and genotyped both potentially functional SNPs and tagging SNPs in MDM2 and p53 using Illumina Golden Gate platform in a cohort of 568 NSCLC patients. Associations between genotypes and NSCLC median survival time (MST) were assessed using the Kaplan-Meier method. Cox proportional hazard models were performed with the adjustment for age, stage, smoking, histology, surgical operation, and chemo-or radiotherapy status. We found that the MDM2 SNP309 (rs2279744) GT/TT genotypes were associated with a significantly worse survival (MST: 23.0 mo for GT/TT vs. 33.0 mo for GG; log-rank P = 0.028). In the multivariate Cox regression analyses, the MDM2 SNP309GT/TT genotypes were associated with a 1.42-fold [HR = 1.42,95% confidence interval (CI), 1.09-1.84] increased risk of death of NSCLC, compared with SNP309GG genotype. MDM2 SNP309 may be used as one of the candidate biomarkers to predict NSCLC survival. (C) 2011 Wiley-Liss, Inc.
引用
收藏
页码:433 / 438
页数:6
相关论文
共 50 条
[31]   Association of p53 and mdm2 in the development and progression of non-small cell lung cancer [J].
Javid, Jamsheed ;
Mir, Rashid ;
Julka, P. K. ;
Ray, P. C. ;
Saxena, Alpana .
TUMOR BIOLOGY, 2015, 36 (07) :5425-5432
[32]   MDM2 SNP309 is an ethnicity-dependent risk factor for digestive tract cancers [J].
Chen, Bo ;
Cao, Lei ;
Hu, Kong-Wang ;
Zhang, Jia-Wei ;
Meng, Xiang-Ling ;
Xiong, Mao-Ming .
TUMOR BIOLOGY, 2014, 35 (04) :3431-3438
[33]   Lack of Association between MDM2 Promoter SNP309 and Clinical Outcome in Patients with Neuroblastoma [J].
Rihani, Ali ;
Van Maerken, Tom ;
De Wilde, Bram ;
Zeka, Fjoralba ;
Laureys, Genevieve ;
Norga, Koen ;
Tonini, Gian Paolo ;
Coco, Simona ;
Versteeg, Rogier ;
Noguera, Rosa ;
Schulte, Johannes H. ;
Eggert, Angelika ;
Stallings, Raymond L. ;
Speleman, Frank ;
Vandesompele, Jo .
PEDIATRIC BLOOD & CANCER, 2014, 61 (10) :1867-1870
[34]   Associations of MDM2 SNP309, Transcriptional Activity, mRNA Expression, and Survival in Stage I Non-Small-Cell Lung Cancer Patients with Wild-Type p53 Tumors [J].
Chien, Wen-Pin ;
Wong, Ruey-Hong ;
Cheng, Ya-Wen ;
Chen, Chih-Yi ;
Lee, Huei .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (04) :1194-1202
[35]   Association of p53 Arg72Pro and MDM2 SNP309 polymorphisms with glioma [J].
Zhang, J. N. ;
Yi, S. H. ;
Zhang, X. H. ;
Liu, X. Y. ;
Mao, Q. ;
Li, S. Q. ;
Xiong, W. H. ;
Qiu, Y. M. ;
Chen, T. ;
Ge, J. W. .
GENETICS AND MOLECULAR RESEARCH, 2012, 11 (04) :3618-3628
[36]   No association of MDM2 SNP309 with risk of glioblastoma and prognosis [J].
Soufiane El Hallani ;
Yannick Marie ;
Ahmed Idbaih ;
Mathieu Rodero ;
Blandine Boisselier ;
Florence Laigle-Donadey ;
François Ducray ;
Jean-Yves Delattre ;
Marc Sanson .
Journal of Neuro-Oncology, 2007, 85 :241-244
[37]   Effects of p53 Codon 72 and MDM2 SNP309 Polymorphisms on Gastric Cancer Risk among the Iranian Population [J].
Moradi, Mohammad-Taher ;
Salehi, Zivar ;
Aminian, Keyvan ;
Yazdanbod, Abbas .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (17) :7413-7417
[38]   The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B-cell lymphoma [J].
Hedstrom, Gustav ;
Thunberg, Ulf ;
Amini, Rose-Marie ;
Zainuddin, Norafiza ;
Enblad, Gunilla ;
Berglund, Mattias .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (06) :500-508
[39]   No association of MDM2 SNP309 with risk of glioblastoma and prognosis [J].
El Hallani, Soufiane ;
Marie, Yannick ;
Idbaih, Ahmed ;
Rodero, Mathieu ;
Boisselier, Blandine ;
Laigle-Donadey, Florence ;
Ducray, Francois ;
Delattre, Jean-Yves ;
Sanson, Marc .
JOURNAL OF NEURO-ONCOLOGY, 2007, 85 (03) :241-244
[40]   Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis [J].
Economopoulos, Konstantinos P. ;
Sergentanis, Theodoros N. .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 120 (01) :211-216